Two nonpeptide tachykinin antagonists act through epitopes on corresponding segments of the NK1 and NK2 receptors.
The molecular mechanism of action for two chemically distinct and highly selective, nonpeptide antagonists, CP-96,345 and SR-48,968, was studied by development of a series of chimeric constructs between their respective target receptors, the NK1 (substance P) and NK2 (neurokinin A) receptors. The binding affinities of the natural peptide ligands, substance P and neurokinin A, were not affected by exchanging almost the entire C-terminal half of the NK1 receptor with the corresponding segment of the NK2 receptor. In contrast, it was found that transfer from the NK2 to the NK1 receptor of a segment corresponding to transmembrane segment VI, the amino-terminal half of transmembrane segment VII, and the connecting extracellular loop 3 completely switched the susceptibility for the nonpeptide antagonists. This chimeric exchange, corresponding to 17 nonconserved residues, conveyed full susceptibility for the NK2-specific compound SR-48,968 to the previously unresponsive NK1 receptor--i.e., the Ki value for inhibition of binding of 125I-labeled substance P decreased from > 10,000 to 0.97 nM. At the same time the affinity for the NK1-selective compound CP-96,345 decreased > 30-fold. The actual binding site for SR-48,968 was localized to this region of the NK2 receptor by use of [3H]SR-48,968, which did not bind to the NK1 receptor but bound with similar high affinities to the wild-type NK2 receptor and to the chimeric NK1 receptor with the NK2 receptor segment incorporated around transmembrane segments VI and VII, Kd = 1.5 nM and 1.0 nM, respectively. Our data indicate that two chemically very different nonpeptide antagonists, CP-96,345 and SR-48,968, act through epitopes located around transmembrane segment VI on their respective target receptors and that at least the nonconserved residues in these epitopes are not important for the binding of the natural peptide ligands, substance P and neurokinin A.
Gether
U
U
Laboratory of Molecular Endocrinology, University Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.
Yokota
Y
Y
Emonds-Alt
X
X
Brelière
J C
JC
Lowe
J A
JA
Snider
R M
RM
Nakanishi
S
S
Schwartz
T W
TW
D000818:Animals; D001549:Benzamides / Q000378:metabolism / Q000494:pharmacology*; D001665:Binding Sites; D001713:Biphenyl Compounds / Q000378:metabolism / Q000494:pharmacology*; D002478:Cells, Cultured; D000939:Epitopes; D015288:Neurokinin A / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010880:Piperidines / Q000378:metabolism / Q000494:pharmacology*; D018040:Receptors, Neurokinin-1; D018041:Receptors, Neurokinin-2; D017981:Receptors, Neurotransmitter / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D013373:Substance P / Q000037:antagonists & inhibitors*
D001549:Benzamides; D001713:Biphenyl Compounds; D000939:Epitopes; D010880:Piperidines; D018040:Receptors, Neurokinin-1; D018041:Receptors, Neurokinin-2; D017981:Receptors, Neurotransmitter; D013373:Substance P; C073839:SR 48968; D015288:Neurokinin A; C066892:CP 96345